{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:27:36Z","timestamp":1791160056949,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40265-014-0322-5","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T22:57:36Z","timestamp":1416005856000},"page":"2175-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"74","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"issue":"6","key":"322_CR1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40265-014-0209-5","volume":"74","author":"M L\u00f6hle","year":"2014","unstructured":"L\u00f6hle M, Ramberg CJ, Reichmann H, et al. Early versus delayed initiation of pharmacotherapy in Parkinson\u2019s disease. Drugs. 2014;74(6):645\u201357.","journal-title":"Drugs."},{"issue":"3","key":"322_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235\u201345.","journal-title":"Lancet Neurol."},{"issue":"4","key":"322_CR3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40263-013-0053-2","volume":"27","author":"F Sprenger","year":"2013","unstructured":"Sprenger F, Poewe W. Management of motor and non-motor symptoms in Parkinson\u2019s disease. CNS Drugs. 2013;27(4):259\u201372.","journal-title":"CNS Drugs."},{"key":"322_CR4","unstructured":"European Parkinson\u2019s Disease Association. Prevalence of Parkinson\u2019s disease. 2014. http:\/\/www.epda.eu.com\/en\/parkinsons\/life-with-parkinsons\/part-1\/prevalence-of-parkinsons-disease\/ . Accessed 10 July 2014."},{"issue":"11","key":"322_CR5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/11537810-000000000-00000","volume":"24","author":"S Perez-Lloret","year":"2010","unstructured":"Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson\u2019s disease. CNS Drugs. 2010;24(11):941\u201368.","journal-title":"CNS Drugs."},{"issue":"2","key":"322_CR6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","volume":"45","author":"D Nyholm","year":"2006","unstructured":"Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson\u2019s disease: an update. Clin Pharmacokinet. 2006;45(2):109\u201336.","journal-title":"Clin Pharmacokinet."},{"issue":"Suppl 3","key":"322_CR7","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","volume":"26","author":"SH Fox","year":"2011","unstructured":"Fox SH, Katzenschlager R, Lim S-Y, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26(Suppl 3):S2\u201341.","journal-title":"Mov Disord."},{"key":"322_CR8","unstructured":"Boehringer Ingelheim International GmbH. MIRAPEXIN 0.26, 0.52, 1.05, 1.57, 2.1, 2.62 and 3.15\u00a0mg prolonged-release tablets: EU summary of product characteristics. 2008. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000134\/WC500029252.pdf . Accessed 26 June 2014."},{"key":"322_CR9","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Mirapex\u00ae (pramipexole dihydrochloride) tablets for oral administration: US prescribing information. 2013. http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6 . Accessed 10 July 2014."},{"key":"322_CR10","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Mirapex ER\u00ae (pramipexole dihydrochloride) extended-release tablets: US prescribing information. 2013. https:\/\/www.mirapexer.com . Accessed 1 July 2014."},{"issue":"8","key":"322_CR11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","volume":"77","author":"W Poewe","year":"2011","unstructured":"Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77(8):759\u201366.","journal-title":"Neurology."},{"issue":"8","key":"322_CR12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AHV Schapira","year":"2011","unstructured":"Schapira AHV, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77(8):767\u201374.","journal-title":"Neurology."},{"issue":"4","key":"322_CR13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11204570-000000000-00000","volume":"24","author":"CM Chwieduk","year":"2010","unstructured":"Chwieduk CM, Curran MP. Pramipexole extended release: in Parkinson\u2019s disease. CNS Drugs. 2010;24(4):327\u201336.","journal-title":"CNS Drugs."},{"issue":"10","key":"322_CR14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1517\/17425255.2011.614232","volume":"7","author":"A Antonini","year":"2011","unstructured":"Antonini A, Calandrella D. Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol. 2011;7(10):1307\u201314.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"3","key":"322_CR15","first-page":"141","volume":"21","author":"MF Piercey","year":"1998","unstructured":"Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21(3):141\u201351.","journal-title":"Clin Neuropharmacol."},{"issue":"6","key":"322_CR16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00002512-199812060-00007","volume":"12","author":"M Dooley","year":"1998","unstructured":"Dooley M, Markham A. Pramipexole: a review of its use in the management of early and advanced Parkinson\u2019s disease. Drugs Aging. 1998;12(6):495\u2013514.","journal-title":"Drugs Aging."},{"key":"322_CR17","first-page":"1","volume":"11","author":"S Hisahara","year":"2011","unstructured":"Hisahara S, Shimohama S. Dopamine receptors and Parkinson\u2019s disease. Int J Med Chem. 2011;11:1\u201316.","journal-title":"Int J Med Chem."},{"issue":"10","key":"322_CR18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00702-003-0027-5","volume":"110","author":"M Gerlach","year":"2003","unstructured":"Gerlach M, Double K, Arzberger T, et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm. 2003;110(10):1119\u201327.","journal-title":"J Neural Transm."},{"issue":"9","key":"322_CR19","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1586\/ern.11.122","volume":"11","author":"E-M Hametner","year":"2011","unstructured":"Hametner E-M, Seppi K, Poewe W. Pramipexole extended release in Parkinson\u2019s disease. Expert Rev Neurother. 2011;11(9):1229\u201334.","journal-title":"Expert Rev Neurother."},{"issue":"7","key":"322_CR20","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.bjp.0702673","volume":"127","author":"MC Coldwell","year":"1999","unstructured":"Coldwell MC, Boyfield I, Brown T, et al. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1999;127(7):1696\u2013702.","journal-title":"Br J Pharmacol."},{"issue":"1","key":"322_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0922-4106(95)90013-6","volume":"290","author":"J Mierau","year":"1995","unstructured":"Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995;290(1):29\u201336.","journal-title":"Eur J Pharmacol."},{"issue":"1","key":"322_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(96)00454-2","volume":"312","author":"MF Piercey","year":"1996","unstructured":"Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996;312(1):35\u201344.","journal-title":"Eur J Pharmacol."},{"issue":"2\u20133","key":"322_CR23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-2999(92)90024-X","volume":"215","author":"J Mierau","year":"1992","unstructured":"Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 1992;215(2\u20133):161\u201370.","journal-title":"Eur J Pharmacol."},{"issue":"12","key":"322_CR24","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1185\/03007990903364954","volume":"25","author":"S Albrecht","year":"2009","unstructured":"Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin. 2009;25(12):2977\u201387.","journal-title":"Curr Med Res Opin."},{"issue":"13","key":"322_CR25","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287(13):1653\u201361.","journal-title":"JAMA."},{"issue":"5","key":"322_CR26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2125.2007.02938.x","volume":"64","author":"ER Samuels","year":"2007","unstructured":"Samuels ER, Hou RH, Langley RW, et al. Comparison of pramipexole with and without domperidone coadministration on alertness, autonomic, and endocrine functions in healthy volunteers. Br J Clin Pharmacol. 2007;64(5):591\u2013602.","journal-title":"Br J Clin Pharmacol."},{"issue":"Suppl 3","key":"322_CR27","first-page":"538","volume":"16","author":"M Koenen-Bergmann","year":"2009","unstructured":"Koenen-Bergmann M, Revollo I, Ring A, et al. Pramipexole does not prolong the QTc interval [abstract]. Eur J Neurol. 2009;16(Suppl 3):538.","journal-title":"Eur J Neurol."},{"key":"322_CR28","doi-asserted-by":"crossref","unstructured":"Farha KA, Balj\u00e9-Volkers C, Tamminga W, et al. Dopamine D2R agonist-induced cardiovascular effects in healthy male subjects: potential implications in clinical settings. ISRN Neurology. 2014. doi: 10.1155\/2014\/956353 .","DOI":"10.1155\/2014\/956353"},{"issue":"11","key":"322_CR29","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.clinthera.2009.10.018","volume":"31","author":"P Jenner","year":"2009","unstructured":"Jenner P, Konen-Bergmann M, Schepers C, et al. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther. 2009;31(11):2698\u2013711.","journal-title":"Clin Ther."},{"issue":"15","key":"322_CR30","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/mds.23317","volume":"25","author":"RA Hauser","year":"2010","unstructured":"Hauser RA, Schapira AHV, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson\u2019s disease. Mov Disord. 2010;25(15):2542\u20139.","journal-title":"Mov Disord."},{"issue":"14","key":"322_CR31","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/mds.23262","volume":"25","author":"O Rascol","year":"2010","unstructured":"Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson\u2019s disease. Mov Disord. 2010;25(14):2326\u201332.","journal-title":"Mov Disord."},{"issue":"5","key":"322_CR32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/ene.12375","volume":"21","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Schapira AHV, Barone P, et al. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson\u2019s disease. Eur J Neurol. 2014;21(5):736\u201343.","journal-title":"Eur J Neurol."},{"issue":"1","key":"322_CR33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1468-1331.2012.03822.x","volume":"20","author":"AHV Schapira","year":"2013","unstructured":"Schapira AHV, Barone P, Hauser RA, et al. Success rate, efficacy, and safety\/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson\u2019s disease. Eur J Neurol. 2013;20(1):180\u20137.","journal-title":"Eur J Neurol."},{"issue":"4","key":"322_CR34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNF.0b013e31825f77b9","volume":"35","author":"Y Mizuno","year":"2012","unstructured":"Mizuno Y, Yamamoto M, Kuno S, et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012;35(4):174\u201381.","journal-title":"Clin Neuropharmacol."},{"key":"322_CR35","doi-asserted-by":"crossref","unstructured":"Wang Y, Sun S, Zhu S, et al. The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson\u2019s disease: a randomized, double-blind, double-dummy, parallel-group study. Transl Neurodegener. 2014;3:11. doi: 10.1186\/2047-9158-3-11 .","DOI":"10.1186\/2047-9158-3-11"},{"key":"322_CR36","unstructured":"European Medicines Agency. Assessment report for Mirapexin. International nonproprietary name: pramipexole. Procedure no.: EMEA\/H\/C\/000134\/X\/0059. 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000134\/WC500029254.pdf . Accessed 3 July 2014."},{"key":"322_CR37","unstructured":"Bergmann K. Center for Drug Evaluation and Research. Application number: 22-514. Medical review(s). 2010. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022514s000MedR.pdf . Accessed 7 July 2014."},{"issue":"16","key":"322_CR38","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670\u201383.","journal-title":"JAMA."},{"key":"322_CR39","doi-asserted-by":"crossref","unstructured":"M\u00fcller T. Drug therapy in patients with Parkinson\u2019s disease. Transl Neurodegener. 2012;1:10. doi: 10.1186\/2047-9158-1-10 .","DOI":"10.1186\/2047-9158-1-10"},{"key":"322_CR40","doi-asserted-by":"crossref","unstructured":"Tambasco N, Simoni S, Marsili E, et al. Clinical aspects and management of levodopa-induced dyskinesia. Park Dis. 2012. doi: 10.1155\/2012\/745947 .","DOI":"10.1155\/2012\/745947"},{"key":"322_CR41","unstructured":"National Institute for Health and Clinical Excellence. Parkinson\u2019s disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35). 2010. http:\/\/www.nice.org.uk\/nicemedia\/pdf\/cg035niceguideline.pdf . Accessed 11 July 2014."},{"issue":"10","key":"322_CR42","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","volume":"24","author":"A Antonini","year":"2010","unstructured":"Antonini A, Barone P, Ceravolo R, et al. Role of pramipexole in the management of Parkinson\u2019s disease. CNS Drugs. 2010;24(10):829\u201341.","journal-title":"CNS Drugs."},{"key":"322_CR43","first-page":"83","volume":"7","author":"E-M Hametner","year":"2012","unstructured":"Hametner E-M, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson\u2019s disease. Clin Interv Aging. 2012;7:83\u20138.","journal-title":"Clin Interv Aging."},{"issue":"4","key":"322_CR44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/cns.12239","volume":"20","author":"C-Q Zhou","year":"2014","unstructured":"Zhou C-Q, Lou J-H, Zhang Y-P, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014;20(4):368\u201376.","journal-title":"CNS Neurosci Ther."},{"issue":"2","key":"322_CR45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/NDT.S2325","volume":"4","author":"R Constantinescu","year":"2008","unstructured":"Constantinescu R. Update on the use of pramipexole in the treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2008;4(2):337\u201352.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"322_CR46","first-page":"33","volume":"5","author":"HA Shill","year":"2009","unstructured":"Shill HA, Stacy M. Update on ropinirole in the treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2009;5:33\u20136.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"Suppl 2","key":"322_CR47","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1007\/s00415-011-6024-y","volume":"258","author":"F Stocchi","year":"2011","unstructured":"Stocchi F. Continuous dopaminergic stimulation and novel formulations of dopamine agonists. J Neurol. 2011;258(Suppl 2):S316\u201322.","journal-title":"J Neurol."},{"key":"322_CR48","unstructured":"Fox SH, Katzenschlager R, Lim S-Y, et al. Update: treatments for motor symptom of Parkinson\u2019s disease. 2012. http:\/\/www.movementdisorders.org\/MDS-Files1\/PDFs\/EBM-Papers\/update-on-treatments-for-motor-symptoms-of-PD.pdf . Accessed 17 Sep 2014."},{"issue":"6","key":"322_CR49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573\u201380.","journal-title":"Lancet Neurol."},{"issue":"10","key":"322_CR50","doi-asserted-by":"crossref","first-page":"e76651","DOI":"10.1371\/journal.pone.0076651","volume":"8","author":"J Liu","year":"2013","unstructured":"Liu J, Dong J, Wang L, et al. Comparative efficacy and acceptability of antidepressants in Parkinson\u2019s disease: a network meta-analysis. PLoS One. 2013;8(10):e76651.","journal-title":"PLoS One."},{"issue":"Suppl 3","key":"322_CR51","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based Medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26(Suppl 3):S42\u201380.","journal-title":"Mov Disord."},{"issue":"1","key":"322_CR52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1468-1331.2012.03712.x","volume":"20","author":"AHV Schapira","year":"2013","unstructured":"Schapira AHV, Barone P, Hauser RA, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson\u2019s disease. Eur J Neurol. 2013;20(1):50\u20136.","journal-title":"Eur J Neurol."},{"issue":"1","key":"322_CR53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/03007995.2012.752351","volume":"29","author":"F Viallet","year":"2013","unstructured":"Viallet F, Pitel S, Lancrenon S, et al. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson\u2019s disease. Curr Med Res Opin. 2013;29(1):23\u201331.","journal-title":"Curr Med Res Opin."},{"issue":"7","key":"322_CR54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/00207454.2012.660586","volume":"122","author":"FJ Zagmutt","year":"2012","unstructured":"Zagmutt FJ, Tarrants ML. Indirect comparisons of adverse events and dropout rates in early Parkinson\u2019s disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci. 2012;122(7):345\u201353.","journal-title":"Int J Neurosci."},{"issue":"5","key":"322_CR55","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601\u20137.","journal-title":"J Neurol."},{"issue":"6","key":"322_CR56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"W Poewe","year":"2007","unstructured":"Poewe W, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320.","journal-title":"Lancet Neurol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0322-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0322-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:39Z","timestamp":1559504499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":56,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0322-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,11]]}}}